Form4insider filings, from the source

SEC Form 4 · accession 0000919574-16-013777

Celator Pharmaceuticals Inc · CPXX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Period of report
Jun 21, 2016
Accepted (ET)
Jun 22, 2016 · 3:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001327467

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Jun 21, 2016G88,571—D2,157,898IBy CDK ASSOCIATES, LLC
Common StockF1,F2Jun 21, 2016G564,222—D1,593,676IBy CDK ASSOCIATES, LLC
Common StockF1,F3Jun 21, 2016G564,222—A564,222ISee Footnote
Common StockF1,F2Jun 21, 2016G1,926—D1,591,750IBy CDK ASSOCIATES, LLC

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

Scott Morenstein, a director of the Issuer, is an employee of Caxton Alternative Management LP, an affiliate of Caxton Corporation.